Analysts flock to raise Novo Nordisk share price target following upgrade

Equity analysts are very positive when it comes to the Novo Nordisk stock, especially after the pharmaceutical firm upgraded its guidance in connection with its Q1 report on Friday.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by marketwire, translated by daniel pedersen

Friday morning last week, Novo Nordisk caught the stock market by surprise when the company released its first quarterly report for 2022 half a week before it was scheduled to be published.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading